ALPS Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.01M | Sell |
112,835
-40,150
| -26% | -$360K | 0.01% | 498 |
|
|
2025
Q1 | $1.15M | Sell |
152,985
-14,507
| -9% | -$109K | 0.01% | 447 |
|
|
2024
Q4 | $1.26M | Buy |
167,492
+9,382
| +6% | +$70.6K | 0.01% | 432 |
|
|
2024
Q3 | $1.2M | Sell |
158,110
-2,893
| -2% | -$22K | 0.01% | 456 |
|
|
2024
Q2 | $995K | Buy |
161,003
+15,597
| +11% | +$96.4K | 0.01% | 465 |
|
|
2024
Q1 | $739K | Buy |
145,406
+7,305
| +5% | +$37.1K | 0.01% | 546 |
|
|
2023
Q4 | $827K | Sell |
138,101
-1,749
| -1% | -$10.5K | 0.01% | 522 |
|
|
2023
Q3 | $990K | Buy |
139,850
+972
| +0.7% | +$6.88K | 0.01% | 450 |
|
|
2023
Q2 | $978K | Buy |
138,878
+16,060
| +13% | +$113K | 0.01% | 501 |
|
|
2023
Q1 | $1.02M | Sell |
122,818
-3,555
| -3% | -$29.6K | 0.01% | 465 |
|
|
2022
Q4 | $1.45M | Buy |
126,373
+24,834
| +24% | +$285K | 0.01% | 363 |
|
|
2022
Q3 | $1.28M | Sell |
101,539
-8,576
| -8% | -$108K | 0.01% | 393 |
|
|
2022
Q2 | $1.17M | Buy |
+110,115
| New | +$1.17M | 0.01% | 442 |
|
|
2018
Q2 | – | Sell |
-132,021
| Closed | -$630K | – | 931 |
|
|
2018
Q1 | $630K | Buy |
132,021
+22,977
| +21% | +$110K | 0.01% | 408 |
|
|
2017
Q4 | $535K | Buy |
109,044
+29,841
| +38% | +$146K | ﹤0.01% | 485 |
|
|
2017
Q3 | $415K | Buy |
79,203
+6,612
| +9% | +$34.6K | ﹤0.01% | 692 |
|
|
2017
Q2 | $404K | Buy |
+72,591
| New | +$404K | ﹤0.01% | 678 |
|
|
2016
Q2 | – | Sell |
-82,476
| Closed | -$233K | – | 612 |
|
|
2016
Q1 | $233K | Sell |
82,476
-14,134
| -15% | -$39.9K | ﹤0.01% | 593 |
|
|
2015
Q4 | $997K | Buy |
+96,610
| New | +$997K | 0.01% | 217 |
|